Phase I study of nilotinib in patients (pts) from Japan with imatinib-resistant Ph plus chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL)

被引：0
|
作者：
Tojyo, A.
Miyazaki, Y.
Usui, N.
Kobyashi, Y.
Okamoto, S.
Oyashiki, K.
Nishimura, M.
Okada, M.
Natori, H.
Tanii, H.
机构：
[1] Univ Tokyo, Tokyo, Japan
[2] Nagasaki Univ Hosp Med & Dent, Nagasaki, Japan
[3] Jikei Univ Hosp, Tokyo, Japan
[4] Natl Canc Ctr, Tokyo, Japan
[5] Keio Univ Hosp, Tokyo, Japan
[6] Tokyo Med Univ Hosp, Tokyo, Japan
[7] Chiba Univ Hosp, Chiba, Japan
[8] Hosp Hyogo Coll Med, Hyoko, Japan
[9] Novartis Pharmaceut, E Hanover, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
17511
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A PHASE I/II STUDY OF NILOTINIB IN JAPANESE PATIENTS WITH IMATINIB-RESISTANT OR -INTOLERANT PH+ CHRONIC MYELOGENOUS LEUKEMIA (CML) OR RELAPSED/REFRACTORY PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
    Usuki, K.
    Urabe, A.
    Tojo, A.
    Maeda, Y.
    Kobayashi, Y.
    Jinnai, I.
    Ohyashiki, K.
    Nishimura, M.
    Kawaguchi, T.
    Tanaka, H.
    Miyamura, K.
    Miyazaki, Y.
    Hughes, T.
    Branford, S.
    Okamoto, S.
    Ishikawa, J.
    Okada, M.
    Usui, N.
    Amagasaki, T.
    Natori, H.
    Naoe, T.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 433 - 434
  • [2] Nilotinib monotherapy in patients with imatinib-resistant or -intolerant PH plus chronic myelogenous leukemia in blast crisis or relapsed/refractory PH plus acute lymphoblastic leukemia
    Ottmann, O.
    Larson, R.
    Kantarjian, H.
    Le Coutre, P.
    Baccarani, M.
    Weitzman, A.
    Giles, F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 207 - 207
  • [3] A phase II study of nilotinib administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph plus acute lymphoblastic leukemia (ALL)
    Larson, R.
    Ottman, O.
    Kantarjian, H.
    le Coutre, P.
    Baccarani, M.
    Weitzman, A.
    Giles, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] Nilotinib in patients with imatinib-resistant or -intolerant chronic myelogenous leukemia in chronic phase (CML-CP): Updated phase II results
    Kantarjian, H. M.
    Giles, F. J.
    Hochhaus, A.
    Bhalla, K. N.
    Ossenkoppele, G. J.
    Gattermann, N.
    Haque, A.
    Gallagher, N.
    Castagnetti, F.
    le Coutre, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph plus CML or relapsed/refractory Ph plus ALL
    Tojo, Arinobu
    Usuki, Kensuke
    Urabe, Akio
    Maeda, Yasuhiro
    Kobayashi, Yukio
    Jinnai, Itsuro
    Ohyashiki, Kazuma
    Nishimura, Miki
    Kawaguchi, Tatsuya
    Tanaka, Hideo
    Miyamura, Koichi
    Miyazaki, Yasushi
    Hughes, Timothy
    Branford, Susan
    Okamoto, Shinichiro
    Ishikawa, Jun
    Okada, Masaya
    Usui, Noriko
    Tanii, Hiromi
    Amagasaki, Taro
    Natori, Hiroko
    Naoe, Tomoki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2009, 89 (05) : 679 - 688
  • [6] A phase II study of nilotinib administered to imatinib resistant and intolerant patients with chronic myelogenous leukemia (CML) in chronic phase (CP)
    Rosti, G.
    le Coutre, P.
    Bhalla, K.
    Giles, F.
    Ossenkoppele, G.
    Hochhaus, A.
    Gattermann, N.
    Haque, A.
    Weitzman, A.
    Baccarani, M.
    Kantarjian, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] A phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to imatinib-resistant and -intolerant patients with chronic myelogenous leukemia (CML) in chronic phase (CP).
    le Coutre, Philipp
    Bhalla, Kapil
    Giles, Francis
    Baccarani, Michele
    Ossenkoppele, Gert J.
    Hochhaus, Andreas
    Gattermann, Norbert
    Rafferty, Teresa
    Haque, Ariful
    Weitzman, Aaron
    Kantarjian, Hagop
    BLOOD, 2006, 108 (11) : 53A - 53A
  • [8] A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib-resistant or intolerant patients (pts) with Ph plus chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph plus acute lymphoblastic leukemia (ALL).
    Giles, F. J.
    Larson, R.
    Le Coutre, P.
    Baccarani, M.
    Tavorath, R.
    Alland, L.
    Kantarjian, H. M.
    Hughes, T.
    Ottmann, O.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 346S - 346S
  • [9] Detection of new mutations in patients (pts) with imatinib-resistant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib.
    Hochhaus, A.
    Saglio, A.
    Kantarjian, H.
    Haque, A.
    Shou, Y.
    Woodman, R. C.
    Hughes, T. P.
    Radich, J. P.
    Martinelli, G.
    Kim, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] A phase II study of nilotinib, a novel tyrosine vinase inhibitor administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph plus acute lymphoblastic leukemia (ALL).
    Ottmann, Oliver
    Kantarjian, Hagop
    Larson, Richard
    le Courte, Philipp
    Baccarani, Michele
    Rafferty, Teresa
    Weitzman, Aaron
    Giles, Francis
    BLOOD, 2006, 108 (11) : 528A - 528A
12345